
ELTX Stock Forecast & Price Target
ELTX Analyst Ratings
Bulls say
Elicio Therapeutics is a promising biopharmaceutical company with a strong focus on developing effective immunotherapies to treat various types of cancer. Their innovative Amphiphile (AMP) technology and successful clinical trials for ELI-002 have positioned them as a leader in the market. With a dedicated CEO and potential for high sales, ELTX has a positive outlook for future growth.
Bears say
Elicio Therapeutics is a biotechnology company that focuses on developing novel immunotherapies for the treatment of cancer. While its proprietary AMP technology has shown potential in preclinical studies, the company's clinical pipeline includes only one candidate, ELI-002 7P, which is currently being evaluated in a Phase 2 study for a limited population of mKRAS pancreatic cancer patients. Furthermore, the company may face financial challenges in the future as it may need to raise additional capital before reaching profitability, which could result in equity dilution. Additionally, regulatory and clinical risks could potentially delay or limit the success of ELI-002 7P.
This aggregate rating is based on analysts' research of Elicio Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ELTX Analyst Forecast & Price Prediction
Start investing in ELTX
Order type
Buy in
Order amount
Est. shares
0 shares